Experience with pharicimab in the treatment of patients with neovascular age-related macular degeneration (clinical cases)

Objective: to present the results of intravitreal application of the new anti-Ang-2 and anti-VEGF-A drug faricimab in the treatment of neovascular age-related macular degeneration (AMD) using three clinical cases. Patients with newly diagnosed neovascular AMD received intravitreal faricimab (Vabismo) at a dose of 6 mg (0.05 ml of solution) every 4 weeks in the amount of 4 “loading” injections, further tactics depended on the dynamics and activity of the disease. The use of faricimab in the treatment of neovascular AMD is due to its effect on two mechanisms of pathogenesis: faricimab independently binds and neutralizes both angiopoietin-2 (stabilizes blood vessels, reduces vascular permeability and reduces inflammation) and VEGF-A (reduces vascular permeability and inhibits neovascularization). In the cases we considered the use of faricimab in clinical practice for the treatment of neovascular AMD has demonstrated high efficacy, long-term stabilization of the achieved results, and the absence of adverse events.